articles and announcements

Latest News

UBE3A
May 30, 2019

Role of UBE3A in the Developing Brain

Your ASF donations hard at work at UNC and Erasmus Medical Center in the Netherlands. This pivotal study demonstrated that UBE3A is most critical in the developing brain and plays a less vital role later on in life. This is […]

Read more
May 30, 2019

ASF AS Clinic at UNC Chapel Hill Studies Anxiety

Anxiety in Angelman Syndrome Important work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is […]

Read more
Global Angelman Syndrome clinic network
December 6, 2018

Angelman Syndrome Foundation Expands Clinic Network Internationally

Comprehensive Clinics Provide Unique Support for Individuals with Angelman Syndrome in Canada and Israel AURORA, Ill. (December 6, 2018) – The Angelman Syndrome Foundation (ASF) expands its Angelman Syndrome Clinic Network through collaboration with international partners: The Children’s Hospital of Eastern Ontario in Ottawa, Canada, and the Edmond and […]

Read more
Ovid Therapeutics logo
December 6, 2018

Clinical Trial of OV101 in Pediatric Patients

On December 6, 2018, Ovid Therapeutics announced plans to move ahead with a single, pivotal Phase 3 trial of once-daily dosing of OV101 in pediatric patients with Angelman syndrome. This is based on its End-of-Phase 2 Meeting with the U.S. […]

Read more
Dr. Mark Zylka
November 22, 2018

Dr. Mark Zylka recognized as a 2017 AAAS Fellow

Congratulations to Dr. Mark Zylka who has been recognized as a 2017 American Association for the Advancement of Science (AAAS) Fellow! The AAAS fellows date back to 1874 and have included such prestigious recipients as Thomas Edison and Margaret Mead. More recently, […]

Read more
November 22, 2018

Newborn Screening Study for Rare Disorders

World’s Largest Newborn Screening Study for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes Launches Nonprofits co-fund feasibility study to test screening tool for 75,000 newborns for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes AURORA, Ill., and WALNUT, Calif. (November 8, […]

Read more